Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QTRX
stocks logo

QTRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
37.94M
+7.91%
-0.480
+60%
36.69M
+20.95%
-0.447
-15.72%
39.00M
+59.34%
-0.423
-45.02%
Estimates Revision
The market is revising Downward the revenue expectations for Quanterix Corporation (QTRX) for FY2025, with the revenue forecasts being adjusted by -0.46% over the past three months. During the same period, the stock price has changed by 69.23%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.46%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.76%
In Past 3 Month
Stock Price
Go Up
up Image
+69.23%
In Past 3 Month
Wall Street analysts forecast QTRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast QTRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
Current: 7.700
sliders
Low
5.00
Averages
6.00
High
7.00
Current: 7.700
sliders
Low
5.00
Averages
6.00
High
7.00
Canaccord
Buy -> Hold
downgrade
$12 -> $5
2025-08-11
Reason
Canaccord
Price Target
$12 -> $5
2025-08-11
downgrade
Buy -> Hold
Reason
Canaccord downgraded Quanterix to Hold from Buy with a price target of $5, down from $12. following the Q2 miss. The firm cites a lack of near-term visibility and catalysts to move the shares higher for the downgrade. Quanterix's results were impacted by increasing headwinds in biopharma and continued National Institutes of Health funding uncertainty, the analyst tells investors in a research note.
Nephron Research
Buy
to
Hold
downgrade
$8
2025-07-09
Reason
Nephron Research
Price Target
$8
2025-07-09
downgrade
Buy
to
Hold
Reason
Nephron Research downgraded Quanterix to Hold from Buy with an $8 price target.
Morgan Stanley
Equal Weight
downgrade
$3
2025-06-02
Reason
Morgan Stanley
Price Target
$3
2025-06-02
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Akoya Biosciences (AKYA) to $1.14 from $3 and keeps an Equal Weight rating on the shares. The firm is updating its model for Akoya's Q1 results and the amended merger agreement proposed by Quanterix (QTRX), the analyst tells investors.
Scotiabank
Sung Nam
Buy
Maintains
$28 → $18
2025-03-25
Reason
Scotiabank
Sung Nam
Price Target
$28 → $18
2025-03-25
Maintains
Buy
Reason
Scotiabank analyst Sung Ji Nam lowered the firm's price target on Quanterix to $18 from $28 and keeps an Outperform rating on the shares. Despite the relatively stronger revenue growth performance compared to its peer group, the company's shares underperformed over the last year, the analyst tells investors. While the firm thinks the operating synergy targets are reasonable, it is less certain about the top line growth potential.
Canaccord Genuity
Kyle Mikson
Strong Buy
Maintains
$20 → $15
2025-03-18
Reason
Canaccord Genuity
Kyle Mikson
Price Target
$20 → $15
2025-03-18
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on Quanterix (QTRX) to $15 from $20 and keeps a Buy rating on the shares. The firm said they continue to viewthe company as undervalued following the company's solid performance in 4Q24. That said, they recognize negative investor sentiment on its merger with Akoya Biosciences (AKYA) may negatively impact share price performance going forward.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Quanterix Corp (QTRX.O) is -4.48, compared to its 5-year average forward P/E of -16.22. For a more detailed relative valuation and DCF analysis to assess Quanterix Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.22
Current PE
-4.48
Overvalued PE
-5.58
Undervalued PE
-26.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-11.88
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.00
Undervalued EV/EBITDA
-24.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.67
Current PS
0.00
Overvalued PS
13.98
Undervalued PS
1.35
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

QTRX News & Events

Events Timeline

(ET)
2025-11-20
16:17:20
Quanterix appoints Bill Donnelly as executive chair
select
2025-11-10 (ET)
2025-11-10
16:02:52
Quanterix Announces Q3 Earnings Per Share of 73 Cents, Exceeding Consensus Estimate of 53 Cents
select
2025-09-10 (ET)
2025-09-10
09:38:15
Leerink Calls CMS Fee Schedule a 'Significant Positive' for Quanterix
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-21Newsfilter
Quanterix Unveils Leadership and Board Changes to Facilitate Future Growth

  • Leadership Appointments: Quanterix Corporation has appointed Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to its Board of Directors, while William Donnelly has been named Executive Chair and Jeffrey Elliott as Lead Independent Director.

  • Strategic Focus: The leadership changes aim to support Quanterix's growth initiatives, including expanding its biomarker offerings and launching new diagnostic tools, particularly for Alzheimer's disease.

  • Board Composition Changes: Paul Meister and David Walt, Ph.D., are stepping down from the Board, leaving Quanterix with a total of nine board members, seven of whom are independent.

  • Future Outlook: The new board members bring extensive experience in life sciences and diagnostics, which is expected to enhance Quanterix's strategic direction and operational alignment as it integrates recent acquisitions and focuses on growth.

[object Object]
Preview
9.0
11-18Newsfilter
Quanterix Unveils Pioneering Study Showcasing Dual GFAP/NfL Blood Test Method for Tailored Monitoring of Multiple Sclerosis

  • Study Findings: A study published in the journal 'Brain' validates the use of serum biomarkers GFAP and NfL for monitoring disease activity and progression in multiple sclerosis (MS), highlighting their complementary roles in assessing both acute relapses and chronic progression.

  • Clinical Implications: The research indicates that elevated GFAP levels are linked to an increased risk of Progression Independent of Relapse Activity (PIRA), addressing a significant unmet need in MS management, while NfL remains the gold standard for predicting relapses.

  • Normative Data Infrastructure: Quanterix Corporation's Simoa technology, combined with extensive normative databases for GFAP and NfL, allows for personalized patient assessments by considering factors like age, sex, and BMI, enhancing the precision of MS monitoring.

  • Future Directions: The study suggests that GFAP levels decrease with fingolimod treatment, potentially revealing new mechanisms for drug action and opening avenues for further drug development and monitoring strategies in MS.

[object Object]
Preview
9.5
11-11NASDAQ.COM
Quanterix Corp Reports Wider Q3 Loss, Falls Short of Expectations

  • Quarterly Loss: Quanterix Corp reported a third-quarter loss of -$33.52 million, or -$0.73 per share, which is a significant increase from last year's loss of -$8.35 million, or -$0.22 per share.

  • Revenue Growth: The company's revenue rose by 12.3% to $40.23 million, compared to $35.81 million in the same period last year.

  • Analyst Expectations: The reported loss missed analysts' expectations, which had anticipated earnings of -$0.53 per share, excluding special items.

  • Future Guidance: Quanterix Corp provided full-year revenue guidance of between $130 million and $135 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Quanterix Corp (QTRX) stock price today?

The current price of QTRX is 7.7 USD — it has increased 2.94 % in the last trading day.

arrow icon

What is Quanterix Corp (QTRX)'s business?

Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.

arrow icon

What is the price predicton of QTRX Stock?

Wall Street analysts forecast QTRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Quanterix Corp (QTRX)'s revenue for the last quarter?

Quanterix Corp revenue for the last quarter amounts to 40.23M USD, increased 12.34 % YoY.

arrow icon

What is Quanterix Corp (QTRX)'s earnings per share (EPS) for the last quarter?

Quanterix Corp. EPS for the last quarter amounts to -0.73 USD, increased 231.82 % YoY.

arrow icon

What changes have occurred in the market's expectations for Quanterix Corp (QTRX)'s fundamentals?

The market is revising Downward the revenue expectations for Quanterix Corporation (QTRX) for FY2025, with the revenue forecasts being adjusted by -0.46% over the past three months. During the same period, the stock price has changed by 69.23%.
arrow icon

How many employees does Quanterix Corp (QTRX). have?

Quanterix Corp (QTRX) has 471 emplpoyees as of December 05 2025.

arrow icon

What is Quanterix Corp (QTRX) market cap?

Today QTRX has the market capitalization of 359.67M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free